Condition: NSCLC · HNSCC · Melanoma · Sponsor: CJ Bioscience, Inc.
Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the unmet medical needs of low response rate and refractoriness to immune checkpoint inhibitors typically observed in this subject population by performing assessments of response, dose limiting toxicities, pharmacodynamic, and the effect on microbiome biomarkers at different dose levels of CJRB-101 combined with pembrolizumab.
This description comes directly from the study's public registry record.
Hyun Kim · +82-2-6078-3456 · clinical.development@cj.net
Always discuss trial participation with your own doctor first.
| University of California, Irvine | Irvine, California, United States | Recruiting |
| University of Pittsburgh | Pittsburgh, Pennsylvania, United States | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
| Severance Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05877430